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INTRODUCTION
Fibrodysplasia ossificans progressiva (FOP; OMIM 135100)
is a rare genetic disorder characterized by the progressive
development of ectopic ossification of the skeletal muscles
and subsequent joint stiffness. The worldwide prevalence of
FOP is estimated to be approximately 1/2,000,000 (1). The
majority of FOP cases are sporadic, but in familial cases,
inheritance is autosomal-dominant with variable expression
(2). Children with FOP appear normal at birth except con-
genital malformations of the great toes or phalanges (3, 4).
However, in general, sporadic episodes of painful soft tissue
swellings (flare-ups) occur during the first decade of life (3).
Even minimal trauma such as minor soft tissue injuries, mus-
cle overstretching, overexertion and fatigue, intramuscular
injections, falls, or influenza-like illnesses may lead to episod-
ic flare-ups (1, 4). These soft tissue nodules rarely regress
spontaneously, and usually they rapidly mature through an
endochondral ossification to form normal lamellar bone (3,
5). Heterotopic ossification in FOP is not random but pro-
ceeds in a direction that is axial to appendicular, cranial to
caudad, and proximal to distal (3). The diaphragm, extraoc-
ular, cardiac, and smooth muscles are characteristically spared
from ossification (3, 6). 
FOP is diagnosed based on clinical and radiographic find-
ings. When established ectopic ossification has been confirmed
in a FOP patient, no remedies are available to improve func-
tional capability. Thus, early diagnosis and the avoidance of
provoking events is essential to delay the onset of catastroph-
ic restriction of motion. Nonetheless, the rates of diagnostic
errors and of inappropriate invasive medical procedures are
astonishing, which is probably caused by a lack of physician
awareness (7).
Recently, FOP was found to be caused by a heterozygous
point mutation of c.617G>A; p.R206H in the gene coding
activin A type I receptor (ACVR1) on chromosome 2q23-
24 (8). This mutation is reported to be recurrent regardless
of races (8-10). To the best of our knowledge, the c.617G>A
mutation is the only one that has been associated with FOP
to date. 
Korean familial FOP patients were included in the previ-
ous multi-center linkage analysis study to locate this disease
locus to ACVR1 gene (8). In the present study, we conduct-
ed mutation analysis of c.617G>A in ACVR1 in sporadic
Korean patients who were clinically and radiologically diag-
nosed or suspected to have FOP. 
MATERIALS AND METHODS
Twelve patients were included in this study. The pheno-
types of the patients are summarized in Table 1. Ten patients
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ACVR1 Gene Mutation in Sporadic Korean Patients with Fibrodysplasia
Ossificans Progressiva
Fibrodysplasia ossificans progressiva (FOP; OMIM 135100) is a rare but extreme-
ly disabling genetic disorder of the skeletal system, and is characterized by the pro-
gressive development of ectopic ossification of skeletal muscles and subsequent
joint ankylosis. The c.617G>A; p.R206H point mutation in the activin A type I recep-
tor (ACVR1) gene has been reported to be a causative mutation of FOP. In the pre-
sent study, mutation analysis of the ACVR1 gene was performed in 12 patients diag-
nosed or suspected to have FOP. All patients tested had a de novo heterozygous
point mutation of c.617G>A; p.R206H in ACVR1. Mutation analysis confirmed a
diagnosis of FOP in patients with ambiguous features, and thus, could be used for
diagnostic purposes. Early confirmation through mutation analysis would allow med-
ical professionals to advise on the avoidance of provoking events to delay catas-
trophic flare-ups of ectopic ossifications. 
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Accepted : 11 July 2008had definite clinical manifestations of FOP, i.e., progressive
ectopic ossification with resultant joint ankylosis (Fig. 1).
Detailed clinical manifestations in some patients (case 7, 8,
and 10) have been reported previously (11). Two patients
(cases 1 & 2) showed ambiguous clinical features. An 8-yr old
boy (case 1) was referred under a diagnosis of hereditary mul-
tiple exostosis. He did not have any restriction of joint motion
except for limitation of terminal flexion in both elbow joints.
No soft tissue mass or ectopic ossification was observed in
this patient except for an osteochondroma-like bony spur on
the right distal humerus. However, he was suspected to have
FOP due to big toe anomalies. A 15-yr-old girl (case 2) vis-
ited complaining of in-toeing gait and calf pain after exer-
cise. Although having mild flexion contractures on both
hip and knee joints, she was athletically active. No ectopic
ossification observed except for osteochondroma-like bony
spurs on both distal femora (Fig. 2A). Big toe anomalies (Fig.
2B) and the 5th finger symphalangism lead us to suspect
FOP. The parents recalled that a subcutaneous painless migrat-
ing scalp nodule had been detected when she was 6 months
old, which spontaneously resolved in 2 weeks. Mutation
analysis revealed heterozygous c.617G>A; p.R206H muta-
tion in ACVR1, and she started to experience series of flare-
up at age of 16 yr.
Mutation analysis
Peripheral blood was obtained from all patients and, if pos-
sible, from their parents (case 1, 2, and 6) after obtaining in-
formed consent. Genomic DNA was extracted from circu-
lating leukocytes using standard procedures. A portion of
genomic DNA encompassing exon 4 of ACVR1 was ampli-
fied by polymerase chain reaction (PCR) using specific pri-
mers (5′ -CCAGTCCTTCTTCCTTCTTCC-3′ , sense and
5′ -AGCAGATTTTCCAAGTTCCATC-3′ , antisense) (8).
PCR products were sequenced directly using an ABI Prism
3700 automated sequencer (Applied Biosystems, Foster City,
CA, U.S.A.). Results were further verified by restriction en-
donuclease digestion of PCR products using Cac8I (New
England Biolabs, Beverly, MA, U.S.A.) and HphI (New Eng-
land Biolabs). 
RESULTS
DNA sequence analysis demonstrated the invariable pres-
ence of a heterozygous point mutation of c.617G>A in all
ten patients with obvious clinical manifestations (Fig. 3A).
The mutation was not detected in any of their family mem-
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*Previous diagnosis when the patients were referred to the authors.
FOP, fibrodysplasia.
Age (yr) of parents at 
birth of the patient Current Previous
Great toe  History of Age (yr) of
Case
age (yr)
Sex
diagnosis*
abnor- migrating onset of Ankylosis Current status
mality nodule ossification Father Mother
1 10 M Hereditary multiple +  - Not yet None Normal life 34 31
exostosis
2 16 F Congenital foot + + 16 Neck Community ambulator 30 27
deformity
3 33 F FOP + + 10 Whole body Bed ridden >45 44
involved
4 15 F FOP + - 6 Neck, shoulder,  Wheel-chair bound 30 31
back, hip, knee
5 19 M FOP + + 5 Neck, shoulder,  Community ambulator 30 27
back
6 6 M Infantile + - 5 Neck, shoulder, Community ambulator 31 29 
fibromatosis back
7 33 F Myositis ossificans + + 2 Whole body   Bed ridden 32 29
involved
8 19 F FOP + + 2 Neck, shoulder, Wheel-chair bound 34 32 
back, hip, knee
9 7 F Myositis ossificans + + 5 Neck, shoulder, Community ambulator 33 31  
back
10 14 F FOP + + 2 Neck, shoulder, Wheel-chair bound 35 28 
back, hip, knee
11 21 F Myositis ossificans + + 11 Neck, shoulder, Community ambulator 32 31 
back, Rt knee
12 12 M FOP + + 9 Neck, back,  Community ambulator 36 32
Rt ankle
Table 1. Pertinent data of the patientsbers tested. In addition to direct DNA sequence analysis, the
presence of c.617G>A mutation was also verified by restric-
tion endonuclease digestion (Fig. 3B). The c.617G>A ACVR1
mutation eliminates a Cac8I site and forms a new HphI site.
The PCR product of 350 bp from the G allele (control-par-
ents) was digested by Cac8I and produced three bands (139,
114, and 97 bp), whereas the A allele (FOP patients) appeared
as two bands (253 and 97 bp). For HphI, PCR products of
controls were not digested (one band) whereas bands of 228
and 122 bp, corresponding to the A allele, were detected for
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Fig. 2. Radiographic findings suggestive of FOP in a patient with ambiguous clinical features (case 2). (A) This patient showed no ectopic
ossification but an osteochondroma-like bony spurs were observed on both distal femora, (B) Big toe abnormalities in this patient showed
a slanting of metatarso-phalangeal joint (hallux valgus deformity).
Fig. 1. Radiographic findings of FOP patients with unambiguous clinical features. Infiltration of paraspinal muscles mimicking a tumorous
condition (A), ossification around the neck (B), thoracolumbar spine (C), and left thigh, which caused permanent loss of motion (D).
A B
A
B C Dall FOP patients (8). 
In two patients (case 1 & 2) with ambiguous clinical fea-
tures, DNA sequence analysis demonstrated and restriction
endonuclease digestion analysis confirmed the presence of a
heterozygous de novo c.617G>A mutation.
DISCUSSION
This is the first report on mutation analysis conducted in
sporadic Korean FOP patients. It shows that all 12 spora-
dic FOP patients had invariable heterozygous mutation of
c.617G>A in ACVR1.
FOP is an extremely rare disorder and most cases are spo-
radic (1). Clinical manifestations of typical FOP are consid-
erably uniform, i.e., usually ectopic ossifications occur and
progress during the first decade of life and most patients are
wheelchair bound by the end of the second decade (1, 3, 6).
Delayed onset of ossification after age 15 yr is quite rare, al-
though reports have been issued concerning mild cases with
a late onset of ossification and unusually slow progression
that remained ambulatory till their mid-forties; however,
these cases were not confirmed by mutational analysis (12).
This diverse clinical course causes diagnostic and counseling
difficulties in patients with atypically mild FOP patients. 
However, diagnosis of FOP can be erratic before the onset
of established ectopic ossification (7, 11). Diagnostic errors
and inappropriate medical procedures, for example, attempts
to remove the heterotopic bone, may lead to explosive new
bone formations and can aggravate the natural history of
FOP (7). Thus, early diagnosis and confirmation of FOP is
essential if such iatrogenic hazards are to be avoided. 
To achieve early diagnosis before the flare-ups of ectopic
ossification, great toe abnormalities and a history of migrat-
ing pre-osseous soft tissue mass on the scalp, neck or back
during infancy or early childhood may be informative (11, 13).
In particular, great toe abnormality is one of the most strin-
gent and unambiguous features of FOP patients, and usual-
ly presents as short, malformed great toes with or without
valgus deviation (6). All patients in the present study also
showed great toe anomaly. However, these clinical manifes-
tations without ectopic ossification only suggest diagnosis
of FOP and cannot confirm it. 
The variable clinical manifestation of FOP argues against
the homogeneity of the FOP mutation (9). Shore et al. (8)
reported that the c.617G>A ACVR1 mutation was not iden-
tified in a family who showed ambiguous FOP features. How-
ever, in the present study, mutational analysis confirmed the
diagnosis even in those with exceptionally mild phenotype,
e.g., in case 2. In a study using in-silico modeling of wild-
type and mutant ACVR1, substitution with histidine (p.R
207H), and only histidine, created a pH-sensitive switch with-
in the activation domain of the receptor that lead to ligand-
indepenent activation of ACVR1 in FOP (1). The mecha-
nism affecting the severity of disease progression remains to
be elucidated. However, our findings demonstrate that muta-
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Fig. 3. Mutation analysis of the ACVR1 in FOP patients with definite clinical manifestations. (A) Direct sequencing of the PCR products of
the ACVR1 showed the presence of the c.617G>A mutation. R=adenine or guanine, (B) Restriction endonuclease digestion of the PCR prod-
uct (350 bp). The G allele (control) was digested by Cac8I to produce three bands, whereas the A allele appeared as two bands. Because
FOP patients were heterozygous for this mutation, the 139 bp and 114 bp bands were also presented. The PCR product not digested with
HphI corresponds to the G allele (control) in contrast to digested products corresponding to the A allele (FOP).
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A Btional analysis of the ACVR1 is helpful for confirming or ex-
cluding a diagnosis of FOP in clinically ambiguous patients.
Furthermore, we recommend mutation analysis in young
patients with the early stigma of FOP, e.g., great toe anoma-
ly and a migrating mass on the scalp, neck or back during
infancy or early childhood, to allow patients to avoid provok-
ing events during earlier life.
The incidence of human spontaneous mutation increases
according to parental age, especially paternal age (14). In the
present study, the mean paternal and maternal age was 34
and 31, respectively. Although paternal ages were over thir-
ties in all cases, we could not determine the effect of parental
age on ACVR1 mutation.
In conclusion, the present study shows that the de novo
c.617G>A; p.R206H heterozygous point mutation in the
ACVR1 is present in all sporadic Korean FOP patients ex-
amined. Moreover, mutation analysis confirms a diagnosis
of FOP in patients with ambiguous features, which enable
the medical personnel to give early appropriate medical advice
concerning the prevention of provoking events with hope
for delay or prevention of catastrophic flare-ups of ectopic
ossifications.
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